|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/08 | |
| A61K 47/10 | |||
| A61K 47/26 | |||
| A61K 31/535 | |||
| A61P 35/00 | |||
| A61K 9/19 |
| (11) | Number of the document | 2114157 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07869800.8 |
| Date of filing the European patent application | 2007-12-21 | |
| (97) | Date of publication of the European application | 2009-11-11 |
| (45) | Date of publication and mention of the grant of the patent | 2021-05-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2007/088645 |
| Date | 2007-12-21 |
| (87) | Number | WO 2008/083101 |
| Date | 2008-07-10 |
| (30) | Number | Date | Country code |
| 871865 P | 2006-12-26 | US |
| (72) |
AMMONS, Steve, US
DUAN, Jian-Xin, US
JUNG, Donald, US
MATTEUCCI, Mark, US
|
| (73) |
ImmunoGenesis, Inc.,
909 Fannin St Suite 2000, Houston TX 77010,
US
|
| (54) | PHOSPHORAMIDATE ALKYLATOR PRODRUG FOR THE TREATMENT OF CANCER |
| PHOSPHORAMIDATE ALKYLATOR PRODRUG FOR THE TREATMENT OF CANCER |